163 related articles for article (PubMed ID: 1673587)
1. Acute and chronic hemodynamic effects of xamoterol in mild to moderate congestive heart failure.
Virk SJ; Qiang FX; Anfilogoff NH; Murray RG; Littler WA; Davies MK
Am J Cardiol; 1991 May; 67(12):48C-52C; discussion 52C-54C. PubMed ID: 1673587
[TBL] [Abstract][Full Text] [Related]
2. The acute effects of intravenous xamoterol ('Corwin', I.C.I. 118, 587) on resting and exercise haemodynamics in patients with mild to moderate heart failure.
Virk SJ; Anfilogoff NH; Lawson N; Sadler AM; Smith SJ; Nuttall A; Murray RG; Littler WA; Davies MK
Eur Heart J; 1989 Mar; 10(3):227-34. PubMed ID: 2565233
[TBL] [Abstract][Full Text] [Related]
3. Effects of xamoterol on resting and exercise haemodynamics in patients with chronic heart failure.
Virk SJ; Davies MK
Br J Clin Pharmacol; 1989; 28 Suppl 1(Suppl 1):15S-22S. PubMed ID: 2572250
[TBL] [Abstract][Full Text] [Related]
4. The effects of the partial beta 1-agonist xamoterol on heart rate and ventricular arrhythmias in patients with mild to moderate heart failure.
Virk SJ; Anfilogoff NH; Lawson N; Qiang F; Murray RG; Littler WA; Davies MK
Eur Heart J; 1990 Oct; 11(10):876-84. PubMed ID: 1979946
[TBL] [Abstract][Full Text] [Related]
5. Xamoterol in severe congestive heart failure: long-term oral treatment, a double-blind randomised study.
Tangø M; Lyngborg K; Mehlsen J; Svendsen TL; Trap-Jensen J
Int J Cardiol; 1992 Jan; 34(1):63-8. PubMed ID: 1347763
[TBL] [Abstract][Full Text] [Related]
6. Exercise capacity, arrhythmias, humoral and chemical parameters during long-term therapy with xamoterol.
Erlemeier HH; Kupper W; Bleifeld W
Int J Cardiol; 1990 Aug; 28(2):197-208. PubMed ID: 1697569
[TBL] [Abstract][Full Text] [Related]
7. Clinical experience of therapy with xamoterol in patients with severe systolic and diastolic dysfunction.
Pouleur H; Hanet C; Rousseau MF
Eur Heart J; 1990 Apr; 11 Suppl A():33-8. PubMed ID: 1971587
[TBL] [Abstract][Full Text] [Related]
8. Digoxin and xamoterol in patients with moderate chronic heart failure. A double-blind, randomized, controlled study.
Sorensen EV; Sterndorff B; Andersen MF; Faergeman O
Cardiovasc Drugs Ther; 1989 Apr; 3(2):203-9. PubMed ID: 2577283
[TBL] [Abstract][Full Text] [Related]
9. Comparative effects of digoxin and xamoterol on arrhythmias in patients with mild to moderate heart failure.
Klein W; Eber B; Rotman B
Angiology; 1992 Apr; 43(4):281-6. PubMed ID: 1348403
[TBL] [Abstract][Full Text] [Related]
10. Lack of tolerance development after long-term administration of the partial beta-adrenoceptor agonist xamoterol.
Erlemeier HH; Kupper W; Bleifeld W
Cardiology; 1990; 77(1):30-9. PubMed ID: 1972349
[TBL] [Abstract][Full Text] [Related]
11. Improvement of left ventricular contractility and relaxation with the beta 1-adrenergic receptor partial agonist xamoterol at rest and during exercise in patients with postinfarction left ventricular dysfunction. A placebo-controlled randomized trial.
de Feyter PJ; Serruys PW; Suryapranata H
Circulation; 1990 Feb; 81(2 Suppl):III99-106. PubMed ID: 1967562
[TBL] [Abstract][Full Text] [Related]
12. [Role of adrenergic beta receptor partial agonists in left ventricular failure of ischemic origin. Value of xamoterol (ICI 118,587, Corwin)].
Rousseau MF; Cheron P; Nannan M; Vincent MF; Lavenne F; Pouleur H
Ann Med Interne (Paris); 1985; 136(3):247-50. PubMed ID: 2862823
[TBL] [Abstract][Full Text] [Related]
13. Review of clinical experience with xamoterol. Effects on exercise capacity and symptoms in heart failure.
Marlow HF
Circulation; 1990 Feb; 81(2 Suppl):III93-8. PubMed ID: 1967561
[TBL] [Abstract][Full Text] [Related]
14. Xamoterol in severe heart failure. The Xamoterol in Severe Heart Failure Study Group.
Lancet; 1990 Jul; 336(8706):1-6. PubMed ID: 1694945
[TBL] [Abstract][Full Text] [Related]
15. Selective beta-1-adrenoceptor partial agonist treatment for congestive heart failure.
Shabetai R
Cardiology; 1990; 77(5):357-66. PubMed ID: 1981492
[TBL] [Abstract][Full Text] [Related]
16. [Effects of xamoterol in moderate cardiac insufficiency].
Kayanakis JG; Larouchi L; Doat P; Grenet B; Fauvel JM; Bounhoure JP
Presse Med; 1989 Apr; 18(13):667-70. PubMed ID: 2566161
[TBL] [Abstract][Full Text] [Related]
17. [The value of xamoterol in moderate ischemic cardiac insufficiency].
Rousseau MF; Cheron P; Vincent MF; Pouleur H; Lavenne F
Ann Cardiol Angeiol (Paris); 1984; 33(4):215-8. PubMed ID: 6147115
[TBL] [Abstract][Full Text] [Related]
18. Effects of xamoterol, a beta 1 adrenoceptor partial agonist, in patients with ischaemic dysfunction of the left ventricle.
Vigholt-Sørensen E; Faergeman O; Snow HM
Br Heart J; 1989 Nov; 62(5):335-41. PubMed ID: 2574049
[TBL] [Abstract][Full Text] [Related]
19. Hemodynamic effects of the beta 1-adrenoceptor partial agonist xamoterol in relation to plasma norepinephrine levels during exercise in patients with left ventricular dysfunction.
Sato H; Inoue M; Matsuyama T; Ozaki H; Shimazu T; Takeda H; Ishida Y; Kamada T
Circulation; 1987 Jan; 75(1):213-20. PubMed ID: 2878742
[TBL] [Abstract][Full Text] [Related]
20. Sympathetic modulation in practice: the German clinical experience.
Kupper W; Erlemeier HH; Bleifeld W
Eur Heart J; 1990 Apr; 11 Suppl A():19-25. PubMed ID: 1971586
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
